Vivos Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael K. Korenko
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1030 N Center Parkway Kennewick WA United States of America 99352
- IPO Date
- Sep 2, 1998
- CIK
- 0001449349
- Website
- radiogel.com
- Similar Companies
- Business
- I did not find relevant search results specifically about Vivos Inc. (Ticker: RDGL) or its latest major company changes based on the initial general queries about company name changes and business descriptions. I will perform a more focused targeted search on Vivos Inc. to gather accurate and up-to-date information regarding its products, services, recent changes, and other relevant details.
Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™
Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™
Vivos' Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants
Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity
Vivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet® Manufacturing
Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering
Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients
Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026
Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing
Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™
Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™
Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update
Vivos Therapeutics Reports Full Year 2025 Financial Results
Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call
Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners
Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market
Contrasting SLR Investment (NASDAQ:SLRC) and Advanced Medical Isotope (OTCMKTS:RDGL)
Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites
Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™
Contrasting Advanced Medical Isotope (OTCMKTS:RDGL) and Hercules Capital (NYSE:HTGC)